Radiopharmaceutical therapy are used to treat a variety of illnesses. When opposed to chemotherapy, even diseases like cancer and oncological disorders can be treated with a safer and more focused method. The field of medicine has been transformed by radiopharmaceuticals.
With an extensive platform of radiopharmaceuticals and nuclear medicine products for diagnostic as well as therapeutic uses, Radiopharm Theranostics has the potential to be the market leader. The company’s goal is to establish itself as a market leader in the creation of radiopharmaceutical medicines with therapeutic applications in underserved medical markets.
Paul Hopper, who also serves as the organization’s Executive Chairman, developed Radiopharm Theranostics. In November 2021, he will list the business on the Australian Stock Exchange. Paul has a wealth of expertise working for worldwide public companies that served industries like healthcare, biotechnology, and medicine. He has a wealth of expertise working for startups and businesses with quick growth in the US, Australia, and Asia. Paul founded the business after realising the potential of radiopharmaceutical materials for therapeutic uses. Along with that, he makes sure to support the business’s rapid expansion and complete the tasks of upholding corporate principles and realising an ambitious goal.
Safe and Effective Diagnostic
Safe radioactive medications called radiopharmaceuticals can be used as diagnostic and therapeutic aids. Small doses of it can be introduced into the bloodstream of patients. A radioisotope is attached to a targeted agent, such as a tiny molecule or an antibody, as part of the procedure. Radiopharm Thernaostics is particularly dedicated to giving patients more hope in their fight against cancer. It operates via two different approaches:
-
-
- Utilizing low energy radiation to diagnose diseases within the body
- Therapeutic, whereby high-energy particle emitters and isotopes are used to target and eradicate tumours and malignant tumours
-
Four unique platforms from Radiopharm Thernaostics use peptides, small compounds, and antibodies. They are Pivalate, Nano-mAbs, AvB6 Integrin, and PSA mAb, and they have been further developed across five Phase 2 and two Phase 1 clinical trials, with 156 patients participating by far. The Radiopharm Thernaostics team of research professionals with extensive experience has effectively unlocked the underlying potentials of radiopharmaceuticals because of their passionate belief in the power of disruptive innovation.
Team of Experts
The Radiopharm Thernaostics team is led by ex-Novartis/Advanced Accelerator Chief Commercial Officer, Riccardo Canevari who has an extensive experience in radiopharmaceuticals. Over his career, he has been involved in several major projects and developments in the concerned niche of expertise. The company emphasizes teamwork and believes in the saying of two heads are better than one.
The company embraces a culture of integrity, that is inclusive and a fun place to work while valuing relationships that are honest, collaborative, and mutually respectful which will result in a win-win all. Radiopharm Thernaostics values partnerships with its physicians, researchers, and medical institutions by considering them essential to its success.
Delivering Positive Results
Radiopharm Thernaostics truly nurtures its team and organizes strategic meetings uniformly. Recently, it has organized a three-day strategic planning meeting in London where the entire team of the company was present. The team succeeded in creating a positive environment in the meeting room with its impressive collective intellectual horsepower. The meeting covered discussion and planning of the company’s clinical trials, manufacturing, business development, and human resource development.
After the London meeting, the company has witnessed a 36% increase in patients for its Phase 1 Her-2 imaging study in breast cancer. The team is planning to move forward to the next stage of development under a US IND filing. The Phase 1 Lantheus/Nanomab PD-L1 imaging study in lung cancer has witnessed an increase of 43 patients. Radiopharm Thernaostics’ Phase 1 compassionate-use AVb6 integrin studying the pancreatic and head and neck cancers had witnessed an 80% increase. Across 3 of the 4 technologies, there is a total of 156 patients treated.
Exploring the potential of radiopharmaceuticals
In the last ten years, the world has witnessed a significant rise in the field of ‘Molecular Imaging’ and ‘Nuclear medicine’ due to the use of radiopharmaceuticals. There has been a rise in radiotherapy practices that are also expanding because of the number of cancer cases and technological advances. Considering the rapid rise of radiopharmaceuticals usage, Radiopharm Theranostics is its leading competitor in the industry with its four promising, novel, and distinct technologies, a deep Phase 1 and 2 clinical balance to develop its drugs for treatment and therapeutic purposes.
Radiopharm Theranostics is striving to improve the treatment of cancer with innovative practices and continually working to achieve this mission.
